Please Wait

Applying Filters...

Technical details about Heparin Sodium, learn more about the structure, uses, toxicity, action, side effects and more

Heparin Sodium

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

107 Suppliers, 79 USDMF, 15 CEP/COS, 25 JDMF, 1 EU WC, 41 KDMF, 35 NDC API, 21 Listed Suppliers

DEVELOPMENTS

21 Drug(s) in Development

21 Drug(s) in Development

PRICE INFORMATION

API Reference Price, API Exports, API Imports, FDF Exports, FDF Imports

INTERMEDIATES

2 Suppliers

2 Suppliers

DOSSIERs // Finished Dosage Forms

382 Dossiers, 236 FDA Orange Book, 73 Europe, 23 Canada, 1 Australia, 11 South Africa, 38 Listed Dossiers

DRUG PRODUCT COMPOSITION

INJECTABLE;INJECTION - 1,000 UNITS/ML, INJECTABLE;INJECTION - 10,000 UNITS/ML, INJECTABLE;INJECTION - 20,000 UNITS/ML, INJECTABLE;INJECTION - 5,000 UNITS/ML, INJECTABLE;INJECTION - 1,000 UNITS/ML, INJECTABLE;INJECTION - 10,000 UNITS/ML, INJECTABLE;INJECTION - 5,000 UNITS/ML

RELATED EXCIPIENT COMPANIES

Suppliers, 6 Actylis, 5 Roquette, 2 Nanjing Well Pharmaceutical, 1 Microlex e.U, 1 Finar, 1 Kerry

EXCIPIENTS BY APPLICATIONS

8 Parenteral, 3 Fillers, Diluents & Binders, 2 Topical, 2 Controlled & Modified Release, 1 Solubilizers, 1 Co-Processed Excipients

GLOBAL SALES INFORMATION

15 US Medicaid Prescriptions, 65 Finished Drug Prices

MARKET PLACE

57 APIs, 33 DOSSIERS // FDF

ANALYTICAL SOLUTION(s)

1 Analytical Solutions, 3 EDQM Standards, 4 USP Standards, 8 JP Standards, 6 Other Ref. Standards

DIGITAL CONTENT

8 Data Compilation & Company Tracker #PharmaFlow, 86 News

Also known as: (2s,3s,4r,5r,6r)-6-{[(2s,3s,4s,5r,6s)-6-{[(2r,3s,4s,5r)-2-carboxy-4,6-dihydroxy-5-(sulfooxy)oxan-3-yl]oxy}-2-hydroxy-4-(sulfomethyl)-5-(sulfooxy)oxan-3-yl]oxy}-3-{[(2r,3r,4r,5s,6r)-3-acetamido-4,5-dihydroxy-6-[(sulfooxy)methyl]oxan-2-yl]oxy}-4,5-dihydroxyoxane-2-carboxylic acid, Hepflush, Chembl526514, Gtpl4214, S01xa14, Bdbm50480251

Molecular Formula

C₂₆H₄₁NO₃₄S₄

Molecular Weight

1039.9 g/mol

InChI Key

ZFGMDIBRIDKWMY-PASTXAENSA-N

A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts.

1 2D Structure

2D Structure

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

(2S,3S,4R,5R,6R)-3-[(2R,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(sulfooxymethyl)oxan-2-yl]oxy-6-[(2S,3S,4S,5R,6S)-6-[(2R,3S,4S,5R)-2-carboxy-4,6-dihydroxy-5-sulfooxyoxan-3-yl]oxy-2-hydroxy-4-(sulfomethyl)-5-sulfooxyoxan-3-yl]oxy-4,5-dihydroxyoxane-2-carboxylic acid

2.1.2 InChI

InChI=1S/C26H41NO34S4/c1-4(28)27-7-9(30)8(29)6(2-52-63(43,44)45)53-24(7)56-15-10(31)11(32)25(58-19(15)21(36)37)55-13-5(3-62(40,41)42)14(60-64(46,47)48)26(59-22(13)38)57-16-12(33)17(61-65(49,50)51)23(39)54-18(16)20(34)35/h5-19,22-26,29-33,38-39H,2-3H2,1H3,(H,27,28)(H,34,35)(H,36,37)(H,40,41,42)(H,43,44,45)(H,46,47,48)(H,49,50,51)/t5-,6+,7+,8+,9+,10+,11+,12-,13-,14+,15-,16-,17+,18+,19-,22-,23?,24+,25+,26-/m0/s1

2.1.3 InChI Key

ZFGMDIBRIDKWMY-PASTXAENSA-N

2.1.4 Canonical SMILES

CC(=O)NC1C(C(C(OC1OC2C(C(C(OC2C(=O)O)OC3C(C(C(OC3O)OC4C(C(C(OC4C(=O)O)O)OS(=O)(=O)O)O)OS(=O)(=O)O)CS(=O)(=O)O)O)O)COS(=O)(=O)O)O)O

2.1.5 Isomeric SMILES

CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@@H]1O[C@H]2[C@@H]([C@H]([C@@H](O[C@@H]2C(=O)O)O[C@H]3[C@@H]([C@H]([C@H](O[C@@H]3O)O[C@H]4[C@@H]([C@H](C(O[C@H]4C(=O)O)O)OS(=O)(=O)O)O)OS(=O)(=O)O)CS(=O)(=O)O)O)O)COS(=O)(=O)O)O)O

2.2 Synonyms

2.2.1 MeSH Synonyms

1. Alpha Heparin

2. Alpha-heparin

3. Heparin

4. Heparin Sodium

5. Heparin, Sodium

6. Heparin, Unfractionated

7. Heparinic Acid

8. Liquaemin

9. Unfractionated Heparin

2.2.2 Depositor-Supplied Synonyms

1. (2s,3s,4r,5r,6r)-6-{[(2s,3s,4s,5r,6s)-6-{[(2r,3s,4s,5r)-2-carboxy-4,6-dihydroxy-5-(sulfooxy)oxan-3-yl]oxy}-2-hydroxy-4-(sulfomethyl)-5-(sulfooxy)oxan-3-yl]oxy}-3-{[(2r,3r,4r,5s,6r)-3-acetamido-4,5-dihydroxy-6-[(sulfooxy)methyl]oxan-2-yl]oxy}-4,5-dihydroxyoxane-2-carboxylic Acid

2. Hepflush

3. Chembl526514

4. Gtpl4214

5. S01xa14

6. Bdbm50480251

7. (2s,3s,4r,5r,6r)-3-[(2r,3r,4r,5s,6r)-3-acetamido-4,5-dihydroxy-6-(sulfooxymethyl)oxan-2-yl]oxy-6-[(2s,3s,4s,5r,6s)-6-[(2r,3s,4s,5r)-2-carboxy-4,6-dihydroxy-5-sulfooxyoxan-3-yl]oxy-2-hydroxy-4-(sulfomethyl)-5-sulfooxyoxan-3-yl]oxy-4,5-dihydroxyoxane-2-carboxylic Acid

2.2.3 Other Synonyms

1. 9005-49-6

2.3 Create Date

2007-12-05

3 Chemical and Physical Properties

Molecular Formula	C₂₆H₄₁NO₃₄S₄
Molecular Weight	1039.9 g/mol
XLogP3	-10.4
Hydrogen Bond Donor Count	14
Hydrogen Bond Acceptor Count	34
Rotatable Bond Count	18
Exact Mass	1039.0392821 g/mol
Monoisotopic Mass	1039.0392821 g/mol
Topological Polar Surface Area	589 Å²
Heavy Atom Count	65
Formal Charge	0
Complexity	2140
Isotope Atom Count	0
Defined Atom Stereocenter Count	19
Undefined Atom Stereocenter Count	1
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Information

1 of 2
Drug Name	Heparin sodium
Drug Label	Intravenous solutions with heparin sodium (derived from porcine intestinal mucosa) are sterile, nonpyrogenic fluids for intravenous administration. They contain no bacteriostat or antimicrobial agent or added buffer. Edetate disodium, anhydrous is ad...
Active Ingredient	Heparin sodium
Dosage Form	Injectable
Route	Injection
Strength	5,000 units/ml; 10,000 units/ml; 20,000 units/ml; 1,000 units/ml
Market Status	Prescription
Company	Hospira; Shenzhen Techdow; Sandoz; Pfizer; Fresenius Kabi Usa; Hikma Maple; Sagent Pharms

2 of 2
Drug Name	Heparin sodium
Drug Label	Intravenous solutions with heparin sodium (derived from porcine intestinal mucosa) are sterile, nonpyrogenic fluids for intravenous administration. They contain no bacteriostat or antimicrobial agent or added buffer. Edetate disodium, anhydrous is ad...
Active Ingredient	Heparin sodium
Dosage Form	Injectable
Route	Injection
Strength	5,000 units/ml; 10,000 units/ml; 20,000 units/ml; 1,000 units/ml
Market Status	Prescription
Company	Hospira; Shenzhen Techdow; Sandoz; Pfizer; Fresenius Kabi Usa; Hikma Maple; Sagent Pharms

5 Pharmacology and Biochemistry

5.1 MeSH Pharmacological Classification

Anticoagulants

Agents that prevent BLOOD CLOTTING. (See all compounds classified as Anticoagulants.)

Fibrinolytic Agents

Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. (See all compounds classified as Fibrinolytic Agents.)

POST ENQUIRY